FHTXFoghorn Therapeutics Inc.

Nasdaq foghorntx.com


$ 8.80 $ -0.39 (-4.21 %)    

Thursday, 12-Sep-2024 15:59:14 EDT
QQQ $ 473.43 $ 0.00 (0 %)
DIA $ 411.97 $ 2.70 (0.66 %)
SPY $ 560.27 $ 0.00 (0 %)
TLT $ 100.12 $ -0.47 (-0.47 %)
GLD $ 237.77 $ 0.18 (0.08 %)
$ 8.88
-- x --
-- x --
-- - --
$ 2.70 - $ 9.75
117,824
na
491.32M
$ 1.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-06-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-04-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-10-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-18-2021 12-31-2020 10-K
16 12-04-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jefferies-initiates-coverage-on-foghorn-therapeutics-with-buy-rating-announces-price-target-of-18

Jefferies analyst Kelly Shi initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price T...

 evercore-isi-group-initiates-coverage-on-foghorn-therapeutics-with-outperform-rating-announces-price-target-of-20

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform ra...

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...

 wedbush-reiterates-outperform-on-foghorn-therapeutics-maintains-13-price-target

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.

 foghorn-prices-110m-registered-direct-offering-of-12743039-common-stock-at-a-price-of-551-per-share-and-pre-funded-warrants-to-purchase-up-to-an-aggregate-of-7220794-shares-of-its-common-stock-at-a-price-of-55099-per-pre-funded-warrant

Foghorn Therapeutics Inc. ("Foghorn") (NASDAQ:FHTX) today announced the pricing of a registered direct offering of 12,7...

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...

 wedbush-reiterates-outperform-on-foghorn-therapeutics-maintains-13-price-target

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.

 hc-wainwright--co-reiterates-buy-on-foghorn-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $20 price...

 wedbush-reiterates-outperform-on-foghorn-therapeutics-maintains-13-price-target

Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $13 price target.

 foghorn-therapeutics-to-present-new-preclinical-data-at-2024-aacr-annual-meeting-reflecting-advances-with-multiple-potential-first-in-class-medicines-including-the-selective-inhibitor-of-brm-fhd-909

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION